Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.
Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Cost of Illness
Female
France
/ epidemiology
Health Care Costs
/ statistics & numerical data
Hospital Bed Capacity
/ standards
Hospital Mortality
/ trends
Humans
Infant
Intensive Care Units
/ economics
Length of Stay
/ statistics & numerical data
Male
Middle Aged
Pneumonia, Pneumococcal
/ diagnosis
Retrospective Studies
Risk Factors
Severity of Illness Index
Community-acquired pneumonia
Comorbidities
Direct costs
Intensive care unit
Long-term outcome
Pneumococcal pneumonia
Streptococcus pneumoniae
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
10 01 2021
10 01 2021
Historique:
received:
12
09
2020
accepted:
16
12
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Community-acquired pneumonia (CAP), especially pneumococcal CAP (P-CAP), is associated with a heavy burden of illness as evidenced by high rates of intensive care unit (ICU) admission, mortality, and costs. Although well-defined acutely, determinants influencing long-term burden are less known. This study assessed determinants of 28-day and 1-year mortality and costs among P-CAP patients admitted in ICUs. Data regarding all hospital and ICU stays in France in 2014 were extracted from the French healthcare administrative database. All patients admitted in the ICU with a pneumonia diagnosis were included, except those hospitalized for pneumonia within the previous 3 months. The pneumococcal etiology and comorbidities were captured. All hospital stays were included in the cost analysis. Comorbidities and other factors effect on the 28-day and 1-year mortality were assessed using a Cox regression model. Factors associated with increased costs were identified using log-linear regression models. Among 182,858 patients hospitalized for CAP in France for 1 year, 10,587 (5.8%) had a P-CAP, among whom 1665 (15.7%) required ICU admission. The in-hospital mortality reached 22.8% at day 28 and 32.3% at 1 year. The mortality risk increased with age > 54 years, malignancies (hazard ratio (HR) 1.54, 95% CI [1.23-1.94], p = 0.0002), liver diseases (HR 2.08, 95% CI [1.61-2.69], p < 0.0001), and the illness severity at ICU admission. Compared with non-ICU-admitted patients, ICU survivors remained at higher risk of 1-year mortality. Within the following year, 38.2% (516/1350) of the 28-day survivors required at least another hospital stay, mostly for respiratory diseases. The mean cost of the initial stay was €19,008 for all patients and €11,637 for subsequent hospital stays within 1 year. One-year costs were influenced by age (lower in patients > 75 years old, p = 0.008), chronic cardiac (+ 11% [0.02-0.19], p = 0.019), and respiratory diseases (+ 11% [0.03-0.18], p = 0.006). P-CAP in ICU-admitted patients was associated with a heavy burden of mortality and costs at one year. Older age was associated with both early and 1-year increased mortality. Malignant and chronic liver diseases were associated with increased mortality, whereas chronic cardiac failure and chronic respiratory disease with increased costs. N/A (study on existing database).
Sections du résumé
BACKGROUND
Community-acquired pneumonia (CAP), especially pneumococcal CAP (P-CAP), is associated with a heavy burden of illness as evidenced by high rates of intensive care unit (ICU) admission, mortality, and costs. Although well-defined acutely, determinants influencing long-term burden are less known. This study assessed determinants of 28-day and 1-year mortality and costs among P-CAP patients admitted in ICUs.
METHODS
Data regarding all hospital and ICU stays in France in 2014 were extracted from the French healthcare administrative database. All patients admitted in the ICU with a pneumonia diagnosis were included, except those hospitalized for pneumonia within the previous 3 months. The pneumococcal etiology and comorbidities were captured. All hospital stays were included in the cost analysis. Comorbidities and other factors effect on the 28-day and 1-year mortality were assessed using a Cox regression model. Factors associated with increased costs were identified using log-linear regression models.
RESULTS
Among 182,858 patients hospitalized for CAP in France for 1 year, 10,587 (5.8%) had a P-CAP, among whom 1665 (15.7%) required ICU admission. The in-hospital mortality reached 22.8% at day 28 and 32.3% at 1 year. The mortality risk increased with age > 54 years, malignancies (hazard ratio (HR) 1.54, 95% CI [1.23-1.94], p = 0.0002), liver diseases (HR 2.08, 95% CI [1.61-2.69], p < 0.0001), and the illness severity at ICU admission. Compared with non-ICU-admitted patients, ICU survivors remained at higher risk of 1-year mortality. Within the following year, 38.2% (516/1350) of the 28-day survivors required at least another hospital stay, mostly for respiratory diseases. The mean cost of the initial stay was €19,008 for all patients and €11,637 for subsequent hospital stays within 1 year. One-year costs were influenced by age (lower in patients > 75 years old, p = 0.008), chronic cardiac (+ 11% [0.02-0.19], p = 0.019), and respiratory diseases (+ 11% [0.03-0.18], p = 0.006).
CONCLUSIONS
P-CAP in ICU-admitted patients was associated with a heavy burden of mortality and costs at one year. Older age was associated with both early and 1-year increased mortality. Malignant and chronic liver diseases were associated with increased mortality, whereas chronic cardiac failure and chronic respiratory disease with increased costs.
TRIAL REGISTRATION
N/A (study on existing database).
Identifiants
pubmed: 33423691
doi: 10.1186/s13054-020-03442-z
pii: 10.1186/s13054-020-03442-z
pmc: PMC7798246
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Références
Intensive Care Med. 2018 Dec;44(12):2162-2173
pubmed: 30456466
Respir Med. 2018 Apr;137:6-13
pubmed: 29605214
Infection. 2018 Oct;46(5):669-677
pubmed: 29974388
Cardiovasc Diabetol. 2018 Apr 18;17(1):57
pubmed: 29669543
Chest. 2018 Feb;153(2):427-437
pubmed: 29017956
mBio. 2011 Jan 25;2(1):e00309-10
pubmed: 21264063
Expert Rev Anti Infect Ther. 2018 Sep;16(9):667-677
pubmed: 30118377
J Support Oncol. 2010 Jan-Feb;8(1):28-34
pubmed: 20235421
Health Serv Res Manag Epidemiol. 2020 Jul 24;7:2333392820939801
pubmed: 32782916
PLoS Med. 2011 Jun;8(6):e1001048
pubmed: 21738449
Am J Respir Crit Care Med. 2004 Apr 15;169(8):910-4
pubmed: 14693672
Medicine (Baltimore). 2008 Nov;87(6):329-334
pubmed: 19011504
Eur J Health Econ. 2018 May;19(4):533-544
pubmed: 28547724
PLoS One. 2016 Feb 05;11(2):e0148741
pubmed: 26849359
Crit Care Med. 2013 May;41(5):1229-36
pubmed: 23591209
Value Health. 2019 Nov;22(11):1329-1344
pubmed: 31708071
Vaccine. 2020 Jan 22;38(4):741-751
pubmed: 31843272
Curr Opin Pulm Med. 2016 May;22(3):212-8
pubmed: 26886878
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Expert Rev Respir Med. 2019 Feb;13(2):139-152
pubmed: 30596308
JAMA. 2018 Jan 2;319(1):62-75
pubmed: 29297082
N Engl J Med. 2015 Jul 2;373(1):93
pubmed: 26132952
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
Aliment Pharmacol Ther. 2019 Jan;49(1):84-90
pubmed: 30485467
Curr Med Res Opin. 2020 Jan;36(1):151-160
pubmed: 31566005
Crit Care. 2018 Jan 18;22(1):8
pubmed: 29347987
Rev Invest Clin. 2016 Sep-Oct;68(5):221-228
pubmed: 27941957
Clin Infect Dis. 2003 Dec 15;37(12):1617-24
pubmed: 14689342
Am J Cardiol. 2015 Aug 15;116(4):647-51
pubmed: 26089009
Open Forum Infect Dis. 2019 Nov 30;6(12):ofz510
pubmed: 31868865
Crit Care Med. 2011 Aug;39(8):1886-95
pubmed: 21516036
Acta Anaesthesiol Scand. 2011 Nov;55(10):1254-60
pubmed: 22092131
Curr Opin Infect Dis. 2013 Apr;26(2):151-8
pubmed: 23426328
Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):785-791
pubmed: 30778705
Clin Infect Dis. 2008 Aug 1;47(3):375-84
pubmed: 18558884
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075
pubmed: 31751323
BMC Infect Dis. 2016 Aug 03;16:367
pubmed: 27487784
Crit Care Med. 2010 Nov;38(11):2108-16
pubmed: 20802324
BMC Infect Dis. 2015 Jan 08;15:2
pubmed: 25566688
BMC Health Serv Res. 2017 Aug 17;17(1):572
pubmed: 28818082